Institut Curie;ABIVAX;UNIVERSITE DE MONTPELLIER;Centre National de la Recherche Scientifique
发明人:
申请号：
EP18305911.2
公开号：
EP3594205A1
申请日:
2018.07.09
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention relates to a compound of formula (I):wherein X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group, a -CRaRbO- group, Y1 represents an aryl group selected from a 2-pyridyl group or a pyrimidinyl group, or alternatively X1-Y1 represents a group (A), X2 represents a -CO-NH- group, a -NH-CO-NH- group, a -OCH2- group, a -NH-CO- group or a -SO2-NH- group, Y2 represents a hydrogen atom, a hydroxyl group or a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.The present invention further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.
